LU92509I2 - Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN) - Google Patents

Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN) Download PDF

Info

Publication number
LU92509I2
LU92509I2 LU92509C LU92509C LU92509I2 LU 92509 I2 LU92509 I2 LU 92509I2 LU 92509 C LU92509 C LU 92509C LU 92509 C LU92509 C LU 92509C LU 92509 I2 LU92509 I2 LU 92509I2
Authority
LU
Luxembourg
Prior art keywords
pharmaceutically acceptable
travatan
travoprost
acceptable derivatives
disclosed
Prior art date
Application number
LU92509C
Other languages
English (en)
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22285486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92509(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of LU92509I2 publication Critical patent/LU92509I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Jellies, Jams, And Syrups (AREA)
LU92509C 1993-08-03 2014-07-25 Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN) LU92509I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/101,598 US5510383A (en) 1993-08-03 1993-08-03 Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension

Publications (1)

Publication Number Publication Date
LU92509I2 true LU92509I2 (fr) 2015-10-21

Family

ID=22285486

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92058C LU92058I2 (fr) 1993-08-03 2012-08-08 Travoprost et ses sels pharmaceutiquement acceptables (TRAVATAN®)
LU92509C LU92509I2 (fr) 1993-08-03 2014-07-25 Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU92058C LU92058I2 (fr) 1993-08-03 2012-08-08 Travoprost et ses sels pharmaceutiquement acceptables (TRAVATAN®)

Country Status (13)

Country Link
US (3) US5510383A (fr)
EP (3) EP1514548B1 (fr)
JP (2) JP2791544B2 (fr)
AT (1) ATE286880T2 (fr)
AU (2) AU690120B2 (fr)
CA (1) CA2129287C (fr)
DE (1) DE69434228T2 (fr)
DK (3) DK1920764T4 (fr)
ES (3) ES2458493T3 (fr)
HK (2) HK1010717A1 (fr)
LU (2) LU92058I2 (fr)
PT (3) PT1920764E (fr)
SI (3) SI0639563T1 (fr)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
AU7680096A (en) * 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
EP0930296B2 (fr) * 1996-09-17 2005-11-02 Asahi Glass Company Ltd. Derives de prostaglandine fluores et medicaments
CA2270349A1 (fr) * 1996-11-01 1998-05-14 Jesse A. May Utilisation d'une combinaison d'inhibiteurs d'anhydrase carbonique et de prostaglandines dans le traitement du glaucome
US6649653B1 (en) 1996-11-12 2003-11-18 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
US6680339B2 (en) 1996-11-12 2004-01-20 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
WO1998020880A2 (fr) * 1996-11-12 1998-05-22 Alcon Laboratories, Inc. 11-halo prostaglandines destinees au traitement du glaucome ou de l'hypertension oculaire
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
US5977173A (en) * 1997-09-09 1999-11-02 Wos; John August Aromatic C16 -C20 -substituted tetrahydro prostaglandins useful as FP agonists
EP1012137B1 (fr) * 1997-09-09 2002-11-06 The Procter & Gamble Company Prostaglandines tetrahydro a substitution aromatique c16-c20, utiles comme agonistes de prostaglandine f
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
NZ513825A (en) 1999-03-05 2001-09-28 Procter & Gamble C 16 unsaturated FP-selective prostaglandins analogs
US6214611B1 (en) 1999-04-12 2001-04-10 Chirotech Technology Limited Process for the preparation of prostaglandin precursors
US6294679B1 (en) * 1999-04-12 2001-09-25 Chirotech Technology Limited Intermediate for the synthesis of prostaglandins
GB9908326D0 (en) * 1999-04-12 1999-06-09 Chirotech Technology Ltd Novel process intermediate for the synthesis of prostaglandins
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
WO2001055102A1 (fr) * 2000-01-28 2001-08-02 Asahi Glass Company, Limited Nouveau derive difluoroprostaglandine
WO2001057015A1 (fr) * 2000-02-01 2001-08-09 Cayman Chemical Company, Inc. 1,15-LACTONES INTERNES DE FLUPROSTENOL ET ANALOGUES DE PROSTAGLANDINE F2α APPARENTES, ET LEUR UTILISATION DANS LE TRAITEMENT DU GLAUCOME ET DE L'HYPERTENSION INTRAOCULAIRE
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
WO2001070705A1 (fr) 2000-03-17 2001-09-27 Alcon, Inc. Derives de 2-acylaminobenzimidazole utilises pour traiter le glaucome
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
US20030119846A1 (en) * 2000-03-17 2003-06-26 Collier Jr Robert J. Compounds with 5-ht activity useful for controlling visual field loss
US6927233B1 (en) 2000-03-17 2005-08-09 Alcon, Inc. 5ht2 agonists for controlling IOP and treating glaucoma
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2004098807A1 (fr) * 2000-11-21 2004-11-18 Barsplice Products, Inc. Procede de fabrication de coupleurs en acier permettant d'assembler des barres d'armature du beton
US20050171054A1 (en) * 2001-01-19 2005-08-04 Helge Rask-Andersen Novel method and composition for local treatment of meniere's disease, tinnitus and/or hearing loss
SE0100158D0 (sv) * 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
US20040198829A1 (en) * 2001-04-23 2004-10-07 Sponsel William Eric Prostanoids augment ocular drug penetration
US20030212107A1 (en) * 2001-05-10 2003-11-13 Kapin Michael A. R-reliprodil for treating glaucoma
GB0112699D0 (en) * 2001-05-24 2001-07-18 Resolution Chemicals Ltd Process for the preparation of prostglandins and analogues thereof
JP2004535418A (ja) * 2001-06-01 2004-11-25 アルコン，インコーポレイテッド ピラノインダゾールおよび緑内障治療への使用
EP1392658A4 (fr) * 2001-06-01 2004-10-13 Alcon Inc Indazoles et indoles nouveaux fusionnes et leur utilisation dans le traitement de glaucomes
BR0210238A (pt) * 2001-06-01 2004-07-20 Alcon Inc Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
US6884816B2 (en) 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
ATE422894T1 (de) * 2002-03-21 2009-03-15 Cayman Chem Co Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom
US20050239872A1 (en) 2002-06-06 2005-10-27 Xavier Billot 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
EP1513523A1 (fr) * 2002-06-06 2005-03-16 Merck Frosst Canada & Co. DERIVES D IMIDAZOLIDINE-2-ONE DISUBSTITUES EN 1,5 UTILES EN TANT QU AGONISTES DU RECEPTEUR EP sb 4 /sb DANS LE TRAITEME NT DE TROUBLES OCULAIRES ET DE MALADIES OSSEUSES
US6864282B2 (en) * 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
CA2495917A1 (fr) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Derives de l'oxazolidin-2-one et de la thiazolidin-2-one antagonistes du recepteur ep4, pour le traitement du glaucome
TWI337881B (en) * 2002-08-29 2011-03-01 Santen Pharmaceutical Co Ltd Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
PL375564A1 (en) * 2002-08-30 2005-11-28 Alcon, Inc. Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
WO2004037786A2 (fr) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Agonistes des recepteurs ep4
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
JP2006510742A (ja) * 2002-11-08 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧治療用眼科組成物
US20040092431A1 (en) * 2002-11-12 2004-05-13 Hellberg Peggy E. Histone deacetylase inhibitors for treating degenerative diseases of the eye
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
AU2003280812A1 (en) 2002-11-18 2004-06-15 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
WO2004054572A2 (fr) * 2002-12-13 2004-07-01 Alcon, Inc. Nouveaux analogues de benzopyranne et leur utilisation pour le traitement du glaucome
US20040225014A1 (en) * 2003-02-14 2004-11-11 Sucampo Ag Method for treating ocular hypertension and glaucoma
CA2530081A1 (fr) * 2003-07-01 2005-01-13 Merck & Co., Inc. Compositions ophtalmiques destinees au traitement d'hypertension oculaire
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
EP1664011A4 (fr) * 2003-09-02 2009-02-25 Merck & Co Inc Compositions ophtalmiques pour le traitement de l'hypertension oculaire
CN102558231B (zh) * 2003-09-04 2015-05-27 默沙东公司 用于治疗高眼压的眼用组合物
WO2005025568A1 (fr) * 2003-09-04 2005-03-24 Merck & Co., Inc. Compositions ophtalmiques pour traiter l'hypertension oculaire
EP1663230A1 (fr) * 2003-09-05 2006-06-07 Novartis AG Compositions contenant des derives de benzo(g)quinoline et des derives de prostaglandine
US20080139652A1 (en) * 2003-11-07 2008-06-12 Yusuke Sakai Pharmaceutical Composition Containing Prostaglandin
WO2005053688A1 (fr) * 2003-11-26 2005-06-16 Alcon, Inc. Furo[2,3-g] indazoles substitues destines au traitement du glaucome
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
AR046890A1 (es) * 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
GB0329620D0 (en) * 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
WO2005079809A1 (fr) * 2004-02-19 2005-09-01 Santen Pharmaceutical Co., Ltd. Gouttes pour les yeux transparentes au latanoprost
JP2005263792A (ja) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd 澄明なラタノプロスト点眼液
CA2560167A1 (fr) * 2004-04-26 2005-11-10 Alcon, Inc. Statines pour le traitement de l'hypertension oculaire et du glaucome
US7563816B2 (en) 2004-07-20 2009-07-21 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
EP1802299A2 (fr) * 2004-10-13 2007-07-04 Merck & Co., Inc. Compositions ophtalmiques de traitement de l'hypertension oculaire
CA2583593A1 (fr) * 2004-10-13 2006-04-27 Merck & Co., Inc. Compositions ophtalmiques servant a traiter l'hypertension oculaire
EP1655021B1 (fr) * 2004-11-09 2008-10-29 Novagali Pharma SA Emulsion huile-dans-eau à basse concentration de l'agent cationique et au potentiel de zéta positif
WO2006062839A1 (fr) * 2004-12-08 2006-06-15 Alcon, Inc. Utilisation de dioxindoindazoles et de dioxoloindazoles pour traiter le glaucome
MX2007008188A (es) * 2005-01-14 2007-08-07 Allergan Inc Ciclopentanos o ciclopentanonas sustituidos como agentes terapeuticos.
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
WO2010102078A1 (fr) 2009-03-04 2010-09-10 Allergan, Inc. Solution ophtalmique améliorée à base de bimatoprost
DK1864666T3 (da) 2005-03-31 2012-10-29 Asahi Glass Co Ltd Beskyttelsesmiddel til en retinal neuronal celle indeholdende prostaglandin-F2-alfa-derivat som aktiv ingrediens
WO2006112313A1 (fr) 2005-04-13 2006-10-26 Ube Industries, Ltd. Agent protecteur pour une cellule neuronale retinienne comprenant un derive d’indazole comme ingredient actif
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
AU2006275263A1 (en) * 2005-08-03 2007-02-08 Merck Frosst Canada Ltd EP4 receptor agonist, compositions and methods thereof
TW200744567A (en) * 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
EP1810967B1 (fr) 2006-01-18 2014-07-30 Chirogate International Inc. Procédé et produits intérmediaires pour la fabrication de prostaglandines
US20070219272A1 (en) * 2006-02-06 2007-09-20 Johan Stjernschantz Novel method and compositions for treatment of tinnitus
KR101382922B1 (ko) * 2006-03-13 2014-04-08 가부시키가이샤 아루떼꾸 우에노 수성 조성물
CA2644716A1 (fr) * 2006-03-13 2007-09-27 Merck & Co., Inc. Compositions ophtalmiques pour le traitement de l'hypertension oculaire
CA2681668C (fr) 2006-03-23 2014-04-01 Michael S. Singer Compositions comprenant des analogues de la prostaglandine f2-alpha et procedes pour reduire la graisse corporelle
CA2653903A1 (fr) * 2006-06-12 2007-12-21 Merck & Co., Inc. Compositions ophtalmiques pour traiter une hypertension oculaire
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
UY30883A1 (es) 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
US7964613B2 (en) 2007-02-28 2011-06-21 Asahi Kasei Pharma Corporation Sulfonamide compound
US20090018204A1 (en) * 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
US8592413B2 (en) * 2008-05-15 2013-11-26 Allergan, Inc. Therapeutic substituted cyclopentanes
US20080275118A1 (en) * 2008-06-12 2008-11-06 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
CA2739571A1 (fr) 2008-10-29 2010-08-26 Aerie Pharmaceuticals, Inc. Sels d'acides amines de prostaglandines
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
WO2010112615A1 (fr) 2009-04-03 2010-10-07 Dsm Ip Assets B.V. Dérivés de lysine fonctionnalisés avec des lipides
EP3053913B1 (fr) 2009-05-01 2018-03-07 Aerie Pharmaceuticals, Inc. Inhibiteurs à double mécanisme pour le traitement d'une maladie
JPWO2011034192A1 (ja) 2009-09-17 2013-02-14 千寿製薬株式会社 ラタノプロストを含有する水性点眼剤、並びにラタノプロストの樹脂への吸着の抑制方法
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US20120322882A1 (en) * 2009-11-09 2012-12-20 Allergan, Inc. Compositions And Methods For Stimulating Hair Growth
EP2389939A1 (fr) 2010-05-28 2011-11-30 Novagali Pharma S.A. Utilisation de prostaglandines F2alpha et analogues pour la cicatrisation des lésions de la cornée et du conjonctif
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
WO2012018324A1 (fr) 2010-08-02 2012-02-09 Athena Cosmetics, Inc. Composition, procédé et kit pour améliorer l'apparence des cheveux
BR112013014021A8 (pt) 2010-12-06 2017-10-03 Follica Inc Métodos para tratamento de calvície e promoção de crescimento de cabelos
ES2579990T3 (es) 2011-01-19 2016-08-18 Terakine Therapeutics, Inc. Métodos y composiciones para tratar el síndrome metabólico
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
US20130310370A1 (en) 2011-02-04 2013-11-21 Kowa Co., Ltd. Drug therapy for preventing or treating glaucoma
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
HU231203B1 (hu) * 2011-12-21 2021-10-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására
WO2013133730A1 (fr) * 2012-03-09 2013-09-12 Instytut Farmaceutyczny Procédé de préparation d'analogues de prostaglandine f2α
US8778981B2 (en) 2012-11-21 2014-07-15 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
HU230744B1 (hu) 2012-11-30 2018-01-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására
US20140275160A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
NO2753788T3 (fr) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
EP3091985B1 (fr) 2014-01-10 2024-05-08 Manistee Therapeutics, Inc. Prostanglandines pour leur utilisation topique dans le traitement des migraines.
HU231214B1 (hu) 2014-03-13 2021-11-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás nagytisztaságú prosztaglandinok előállítására
WO2015200425A1 (fr) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Forme posologique à usage topique
BR112017007095B1 (pt) * 2014-10-15 2023-03-14 Alcon Inc Conjugados e derivados de prostaglandina, seu uso, e composição farmacêutica oftálmica
US11285163B2 (en) 2014-10-20 2022-03-29 Sentiss Pharma Private Limited Ophthalmic solution
EP3223793B1 (fr) 2014-11-25 2023-06-28 Eximore Ltd. Compositions et procédés d'administration d'un agent bio-actif ou d'agents bio-actifs
WO2016155906A1 (fr) 2015-03-31 2016-10-06 Nicox S.A. Dérivés de fluprosténol donneurs d'oxyde nitrique
KR20180084759A (ko) 2015-09-27 2018-07-25 폴리카 인코포레이티드 니들링 장치 및 약물 도포기
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
DE102016110381A1 (de) * 2016-06-06 2017-12-07 Edwin Kohl Kosmetische Zusammensetzung, insbesondere zur Förderung des Haarwuchses
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
JP6907319B2 (ja) 2016-08-31 2021-07-21 アエリエ ファーマシューティカルズ インコーポレイテッド 眼科用組成物
EP3609871A4 (fr) 2017-03-31 2021-01-06 Aerie Pharmaceuticals, Inc. Composés d'amide aryl cyclopropyl-amino-isoquinolinyl
CA3112391A1 (fr) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Composes d'amide aryl cyclopropyl-amino-isoquinolinyl

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE37602B1 (en) * 1971-05-11 1977-08-31 Ici Ltd Cyclopentane derivatives
GB1350971A (en) * 1971-05-11 1974-04-24 Imp Chemi Als Ind Ltd Cyclopentane derivatives
GB1451798A (en) * 1973-08-02 1976-10-06 Ici Ltd Prostanoic acid derivatives
GB1486832A (en) * 1974-08-05 1977-09-28 Ici Ltd Prostanoic acid derivatives
DE2523676A1 (de) * 1975-05-26 1976-12-16 Schering Ag Neue prostanderivate und verfahren zu ihrer herstellung
NL7605381A (nl) * 1975-05-26 1976-11-30 Schering Ag Werkwijze voor het bereiden van prostaanderi- vaten en werkwijze voor het bereiden van een geneesmiddel met prostaglandinewerking.
US4159343A (en) * 1975-05-26 1979-06-26 Schering Aktiengesellschaft Prostane derivatives
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
ES2052735T3 (es) * 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
US5173507A (en) * 1988-07-18 1992-12-22 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
ATE101342T1 (de) * 1988-09-06 1994-02-15 Kabi Pharmacia Ab Prostaglandinderivate zur behandlung des gruenen stars oder einer okularen hypertension.
ATE111736T1 (de) * 1988-10-01 1994-10-15 R Tech Ueno Ltd Okulare hypotensive mittel.
CA2031469A1 (fr) * 1989-12-28 1991-06-29 Larry A. Wheeler Utilisation de composes d'inclusion de prostaglandines avec des cyclodextrines dans le traitement de l'hypertension oculaire
HU212570B (en) † 1991-06-24 1996-08-29 Chinoin Gyogyszer Es Vegyeszet Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
US5288754A (en) * 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
DE69311361T2 (de) * 1992-10-13 1998-01-08 Alcon Lab Inc Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension

Also Published As

Publication number Publication date
ES2458493T8 (es) 2014-08-27
AU704670B2 (en) 1999-04-29
PT1514548E (pt) 2014-04-22
SI1920764T1 (sl) 2012-08-31
JP2791544B2 (ja) 1998-08-27
DK1920764T3 (da) 2012-07-02
EP0639563A3 (fr) 1996-10-16
LU92058I2 (fr) 2012-10-08
SI1920764T2 (sl) 2020-03-31
US5665773A (en) 1997-09-09
EP0639563B1 (fr) 2005-01-12
JPH07165703A (ja) 1995-06-27
CA2129287A1 (fr) 1995-02-04
PT639563E (pt) 2005-05-31
ES2235158T3 (es) 2005-07-01
ES2235158T5 (es) 2016-05-25
HK1072716A1 (en) 2005-09-09
EP1920764B1 (fr) 2012-05-16
PT1920764E (pt) 2012-07-20
EP1514548B1 (fr) 2014-02-26
ES2385267T5 (es) 2020-07-21
EP1920764A1 (fr) 2008-05-14
SI0639563T1 (en) 2005-06-30
AU6877994A (en) 1995-02-23
ATE286880T2 (de) 2005-01-15
ES2385267T3 (es) 2012-07-20
DE69434228T2 (de) 2006-02-02
JP3650258B2 (ja) 2005-05-18
EP0639563B2 (fr) 2015-09-30
HK1010717A1 (en) 1999-06-25
EP0639563A2 (fr) 1995-02-22
DK1920764T4 (da) 2020-03-16
SI1514548T1 (sl) 2014-04-30
DE69434228D1 (de) 2005-02-17
DK0639563T4 (en) 2016-01-11
AU7748898A (en) 1998-10-01
DK0639563T3 (da) 2005-03-21
ES2458493T3 (es) 2014-05-05
US5510383A (en) 1996-04-23
EP1514548A2 (fr) 2005-03-16
CA2129287C (fr) 2002-05-14
JPH10182465A (ja) 1998-07-07
AU690120B2 (en) 1998-04-23
DK1514548T3 (da) 2014-03-17
EP1514548A3 (fr) 2005-04-06
EP1920764B2 (fr) 2020-01-08
US5889052A (en) 1999-03-30

Similar Documents

Publication Publication Date Title
LU92509I2 (fr) Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN)
LU91541I2 (fr) latanoprost et ses dérivés pharmaceutiquement acceptables (XALATAN)
DE69834638D1 (de) Heilende zusammensetzung für intraokulare hypertension oder glaukom
SE9401087D0 (sv) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
NO973122D0 (no) Middel for å minske okular spenning
ATE289817T1 (de) Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom
NO20020475D0 (no) 2-aminotetralinderivater for terapi av glaukom
EP1300149A3 (fr) Dérivés de prostaglandines servant au traitement du glaucome ou de l'hypertension oculaire